Skip to main content

Table 3 siRNA cancer therapeutics in clinal trials

From: Research progress on non-protein-targeted drugs for cancer therapy

Target

Drug name

Cancer

ClinicalTrials. gov Identifier

Current status

RRM2

CALAA-01

Solid tumor

NCT00689065

Phase I terminated

PKN3

Atu027

Advanced solid cancer

NCT00938574

Phase I completed

Atu027

Advanced or metastatic pancreatic cancer

NCT01808638

Phase Ib/IIa completed

KRAS

siG12D LODER

Pancreatic cancer

NCT01188785

Phase I completed

siG12D LODER

Pancreatic Cancer

NCT01676259

Phase II recruiting

NBF-006

NSCLC, pancreatic cancer, CRC

NCT03819387

Phase I recruiting

KrasG12D mutation

KRAS G12D siRNA

Pancreatic cancer

NCT03608631

Phase I recruiting

PLK1

TKM-080301

CRC

NCT01437007

Phase I completed

TKM-080301

HCC

NCT02191878

Phase I/II completed

EphA2

siRNA-EphA2 DOPC

Advanced or recurrent solid tumors

NCT01591356

Phase I recruiting

MYC

DCR-MYC

Solid tumors, multiple myeloma, lymphoma

NCT02110563

Phase I terminated

DCR-MYC

HCC

NCT02314052

Phase Ib/II terminated

Bcl2L12

NU-0129

GBM

NCT03020017

Early Phase I completed

TLR9/STAT3

CpG-STAT3 siRNA CAS3/SS3

B-cell non-hodgkin lymphoma

NCT04995536

Phase I recruiting

TGF-β1/COX-2

STP705

Squamous cell carcinoma

NCT04844983

Phase II recruiting

  1. RRM2 M2 subunit of ribonucleotide reductase, PKN3 protein kinase N3, KARS kirsten rat sarcoma, PLK1 polo-like kinase-1, COX-2 cyclooxygenase-2, NSCLC non-small cell lung cancer, CRC colorectal cancer, HCC hepatocellular carcinoma, GBM glioblastoma